Although overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved, several posttransplant complications remain significant issues, including infectious disease and GVHD. One promising approach to these complications is nutritional intervention, for instance glucose control. Previous studies showed that post-transplant hyperglycemia was a risk factor for morbidities like infectious diseases and GVHD. 1, 2 Our group previously performed a pilot study that assessed the feasibility of intensive glucose control (IGC) after allo-HSCT and compared the results with patients in a matched control group. 3 We found that supraphysiological doses of insulin (median dose, 50 IU/day) were required to maintain blood glucose (BG) levels within the target range (80-110 mg/dL). 3 In addition, even though the mean BG level in the IGC group was significantly lower than that in the control group, the proportion of BG values within the normal range was still unsatisfactory in the IGC group. 3 It is difficult to achieve IGC, as shown by the failure in an intensive care unit setting. 4 As such, clarification of the mechanisms underlying post-HSCT hyperglycemia is critical. Hyperglycemia may be caused by decreased insulin secretion or by elevated insulin resistance (IR). After allo-HSCT, calcineurin inhibitors reduce the secretion of insulin, and corticosteroids and inflammatory cytokines elevate IR. 5 In this study, we sought to clarify the main cause of hyperglycemia during the early phase after HSCT by prospectively monitoring patients' post-HSCT glycemic status, including BG levels, C-peptide levels and immunoreactive insulin levels.
From October 2008 to September 2009, a total of 92 patients who received HSCT were enrolled in this prospective observational study. Two patients were excluded due to the withdrawal of approval (n = 1) and death before transplant (n = 1). We also excluded patients who received autologous HSCT (n = 11) and patients who had pretransplant diabetes mellitus (n = 4). The remaining patients (n = 75) were included in our analyses. This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan. All participants provided written informed consent. Enrolled patients received our institutional glucose management protocol and nutritional support protocol. The nutritional support protocol was described previously. 3 The target BG level was set between 80 and 110 mg/ dL when patients were enrolled in the ongoing IGC study. Other patients had a target BG level of o 150 mg/dL, as specified by our institution. Following the protocol, 68 out of 75 patients (91%) received insulin and 58 out of 75 patients (77%) received total parenteral nutrition during the observation period. All patients were managed as inpatients at least up to day 28. In this study, 12 patients received systemic steroid, starting at a median of 40 days after allogeneic HSCT (range 29-52). Glycemic status was monitored before the conditioning regimen, on the day of transplant, and weekly for up to 1 month after transplant. Blood was drawn at the steady fasting state in the morning.
We used the homeostatic model assessment (HOMA) score to provide a noninvasive estimate of IR (HOMA-IR), using the following formula: (fasting insulin (μU/mL) × fasting BG (mg/dL))/405. 6 The HOMA score has been shown to correlate with results of the insulin clamp technique, and has been used for the assessment of glycemic status in intensive care units. [6] [7] [8] To estimate insulin secretion we used the C-peptide level, due to the possible persistence of administered insulin. For the statistical analysis, the Mann-Whitney and Wilcoxon rank-sum tests (paired) were used to compare the differences between the two groups. Spearman's test was used to assess the correlation between C-reactive protein (CRP) and HOMA-IR. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0). 9 More precisely, it is a modified version of R commander (version 1.6-3) that was designed to add statistical functions that are frequently used in biostatistics.
Patients' characteristics are summarized in Table 1 . The median age was 47 years (range, 17-69). The median body mass index was 21.6 kg/m 2 (range, 13.6-30.2). Serial changes in BG and C-peptide levels are shown in Figures 1a and b . The mean BG levels at all time points after HSCT were significantly higher than those before the conditioning regimen (days 0, 7, 14, 21, 28, P o 0.05, Figure 1a ), even though all were still within our institution's target range (o 150 mg/dL). During the study period, 48 out of 75 patients (64%) had fasting blood sugars 4126 mg/dL. Mean serum C-peptide levels were significantly higher at day 0 and day 7 compared with the pretransplant level (Po 0.05, Figure 1b) . After day 0, serum C-peptide decreased gradually and was significantly lower at day 28 compared with the pretransplant value (Po 0.05). Regarding body weight, there was no statistically significant difference between pre-and post-transplant values for up to 1 month (data not shown).
HOMA-IR values were significantly higher at all time points after HSCT than before transplant (days 0, 7, 14, 21, 28, P o 0.05, Figure 1c) . Patients who received a myeloablative conditioning regimen had higher HOMA-IR values at day 14 and day 21 compared with patients who received a reduced-intensity conditioning regimen (P o 0.05, Supplementary Figure 1A) . As we expected serum CRP level to affect the IR level, we analyzed the trend in serum CRP level (Figure 1d ) and assessed the correlation between HOMA-IR and CRP. There was a statistically significant correlation between log(CRP) and log(HOMA-IR) at days 7, 14, 21 and 28 (Figure 1e and Supplementary Figures 1B-D) . There was no correlation between CRP level and C-peptide level at all time points. In this study, the cumulative incidence of grade II-IV acute GVHD was 39.1%. The cumulative incidence of grade II-IV acute GVHD in patients with high HOMA-IR value at day 14 (HOMA-IR ⩾ 4.0) was significantly higher than those with low HOMA-IR value at day 14 (45.5% vs 17.6%, P = 0.04, Supplementary Figure 1E ), although there was no impact on grade III-IV acute GVHD and NRM.
In this study, we prospectively assessed the change of glycemic status in patients who underwent HSCT. The most striking finding was the significant increase in IR. The mean HOMA-IR value was already elevated at day 0 and increased to three times the baseline score at 2 weeks after allo-HSCT. Post-HSCT inflammation is a possible cause of elevated IR. 10 Several studies demonstrated that levels of inflammatory cytokines were elevated even during the conditioning regimen, 11, 12 suggesting that these cytokines could cause increased IR quite early after HSCT. Our finding that the HOMA-IR score was higher in patients who received a myeloablative conditioning regimen than a reducedintensity conditioning regimen also supported this idea.
From day 7 to day 28, we demonstrated a significant correlation between elevated CRP level and higher HOMA-IR value. This suggests that, as with sepsis, 13 inflammation causes IR and thus leads to increased BG levels. Therefore, hyperglycemia early after allogeneic HSCT might reflect increased inflammation. As our group previously reported, CRP level peaked during the neutropenic period.
14 After engraftment, inflammation relating to infectious diseases resolved as reflected by CRP level. We assume that HOMA-IR value might decrease following the improvement of infectious diseases and inflammation, which is associated with engraftment.
The present study also found that insulin secretion, as assessed by serum C-peptide level, increased transiently but then gradually decreased. The initial elevation of C-peptide probably reflects a compensatory mechanism in the face of elevated IR, as found in type 2 diabetes mellitus. The later decline in C-peptide level could be due to the exhaustion of insulin or the effect of calcineurin inhibitors. The finding that the C-peptide level at day 28 was significantly lower than that before transplantation was consistent with our previous report. 15 Such insufficient insulin production is also an important factor for the development of hyperglycemia. In terms of calcineurin inhibitors, patients' glycemic status did not differ significantly whether they were receiving tacrolimus or cyclosporine, but this may have been due to the limited number of patients who received cyclosporine as GVHD prophylaxis, as shown in Table 1 . Considering the previously reported association between posttransplant hyperglycemia and inferior outcome, it is suggested that BG levels should be closely monitored and high-dose insulin should be administered for glucose control after allo-HSCT. 1, 3 The limitations of this study should be clarified. One major limitation is the use of HOMA-IR to assess the IR in this study. In patients with exogenous insulin, the validity of HOMA-IR is not well established, although previous studies used HOMA-IR in such a setting. 7, 8 Therefore, the validity of HOMA-IR has to be reconfirmed using a hyperinsulinemic-euglycemic clamp. In addition, patients in this study had heterogeneous backgrounds, for instance in terms of conditioning regimen and calcineurin inhibitor. Therefore, our analysis might include uncontrolled confounding variables, especially in the subgroup analysis.
In conclusion, in this prospective observational study we serially monitored patients' glycemic status after HSCT and found significant elevations in IR during the early phase post HSCT. Close monitoring of glucose levels and high-dose insulin therapy are necessary to improve glucose control after HSCT.
